Zelira in the news
Articles
For media related enquiries please contact Damien Carbon at Profile Media
Ph: +61 (0) 412 332 122 E: damienc@profilemedia.com.au
Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) final clinical report for a Phase 1 dose escalation trial in chronic pain patients on long-term high-dose opioid treatment shows that the primary and secondary endpoints for safety and efficacy were met.
Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints